GAMMA Investing LLC Invests $44,000 in Galapagos NV (NASDAQ:GLPG)

GAMMA Investing LLC acquired a new stake in Galapagos NV (NASDAQ:GLPG) during the 4th quarter, HoldingsChannel.com reports. The fund acquired 1,161 shares of the biotechnology company’s stock, valued at approximately $44,000.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of the company. Acadian Asset Management LLC raised its holdings in shares of Galapagos by 173.8% during the third quarter. Acadian Asset Management LLC now owns 19,149 shares of the biotechnology company’s stock valued at $661,000 after buying an additional 12,154 shares during the last quarter. FMR LLC increased its position in Galapagos by 0.7% in the 3rd quarter. FMR LLC now owns 4,317,676 shares of the biotechnology company’s stock valued at $149,176,000 after acquiring an additional 28,497 shares during the period. China Universal Asset Management Co. Ltd. raised its stake in Galapagos by 357.6% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 2,265 shares of the biotechnology company’s stock valued at $92,000 after acquiring an additional 1,770 shares in the last quarter. Citigroup Inc. boosted its position in Galapagos by 7,243.0% during the 3rd quarter. Citigroup Inc. now owns 90,686 shares of the biotechnology company’s stock worth $3,133,000 after acquiring an additional 89,451 shares during the period. Finally, Hudson Bay Capital Management LP grew its stake in shares of Galapagos by 7.7% in the third quarter. Hudson Bay Capital Management LP now owns 350,000 shares of the biotechnology company’s stock worth $12,092,000 after purchasing an additional 25,000 shares in the last quarter. 32.46% of the stock is owned by institutional investors and hedge funds.

Galapagos Trading Down 1.2 %

Shares of Galapagos stock opened at $29.09 on Friday. Galapagos NV has a 52 week low of $28.30 and a 52 week high of $45.21. The stock has a market cap of $1.92 billion, a PE ratio of -12.70 and a beta of 0.27. The company’s 50-day moving average price is $32.11 and its two-hundred day moving average price is $36.00.

Wall Street Analysts Forecast Growth

GLPG has been the topic of a number of recent analyst reports. StockNews.com cut shares of Galapagos from a “buy” rating to a “hold” rating in a research note on Monday, March 18th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $38.00 price target on shares of Galapagos in a research note on Monday, April 22nd. Finally, Bank of America reiterated an “underperform” rating and set a $31.00 price objective (down previously from $41.00) on shares of Galapagos in a research note on Thursday, March 28th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $34.50.

Galapagos Profile

Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that has completed phase 1b trial; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; GLPG5201, a CD19 CAR-T product candidates manufactured at point-of-care, currently in phase 1/2 trial in replapsed/refractory chronic lymphocytic leukemia; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma.